177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial

By afschroeder • October 13, 2026

Kishan AU, Wilhalme H, Felix C, Enke J, Ali FZ, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Parmisano S, Brisbane W, Marks L, Singer AE, Rettig MB, Reiter RE, Valle LF, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J. ¹⁷⁷Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial. Eur Urol. 2026 Oct 12:S0302-2838(26)02376-6. doi: 10.1016/j.eururo.2026.09.005. Epub ahead of print. PMID: 42864228.

Tags: Cardiology/Epi, DOM STAT, General Internal Medicine, Hematology/Oncology, Metastasis-directed therapy, oligometastatic, PSMA, Publications, radioligand, Veterans Administration

Coronary Plaque Burden and Progression in Los Angeles Firefighters Versus Matched Controls: A Cohort Study

Hoque A, Kinninger A, Roy SK, Budoff M. Coronary Plaque Burden and Progression in Los Angeles Firefighters Versus Matched Controls: A Cohort Study. J Occup[...]

Development and Validation of a Coronary Artery Calcium Volume and Density Score

Bhatia HS, Razavi AC, Dardari Z, McClelland RL, Jacobs DR Jr, Terry JG, Carr JJ, Duprez D, Joshi PH, Rohatgi A, Khera A, Rana JS,[...]

Oral Anticoagulant Monotherapy vs. Combination Therapy in Chronic Coronary Syndrome Requiring Long-Term Anticoagulation: An Updated Meta-Analysis of Randomized Controlled Trials

Sarwar M, Daniyal SM, Noor A, Riaz M, Batool F, Gondal HT, Murad Khatoon N, Fahim SL, Aftab Z, Ajaz H, Gul I, Khalid A,[...]